ResMed Inc. (RMD) Financial Statements
ResMed Inc. (RMD) reported trailing twelve-month revenue of $5.7B (up 9.9% year on year) and net income of $1.5B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.6B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RMDResMed Inc.Follow RMD — free
—
Price chart with a free account
- Market cap
- 36.5B
- P/E TTM
- 24.2
- Dividend yield
- 0.9%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Jun 11 | FY2012 Jun 12 | FY2013 Jun 13 | FY2014 Jun 14 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Jun 20 | FY2021 Jun 21 | FY2022 Jun 22 | FY2023 Jun 23 | FY2024 Jun 24 | FY2025 Jun 25 | FY2026 Jun 26 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24 | 1.37 | 1.51 | 1.55 | 1.68 | 1.84 | 2.07 | 2.34 | 2.61 | 2.96 | 3.20 | 3.58 | 4.22 | 4.69 | 5.15 | 5.65 | 5.65 | |
| Gross profit | 0.74 | 0.82 | 0.94 | 0.99 | 1.01 | 1.07 | 1.20 | 1.33 | 1.49 | 1.72 | 1.84 | 2.02 | 2.36 | 2.66 | 3.05 | 3.45 | 3.45 | |
| Research & development | 0.09 | 0.11 | 0.12 | 0.12 | 0.11 | 0.12 | 0.14 | 0.16 | 0.18 | 0.20 | 0.23 | 0.25 | 0.29 | 0.31 | 0.33 | 0.38 | 0.38 | |
| Operating income | 0.27 | 0.29 | 0.35 | 0.41 | 0.41 | 0.43 | 0.43 | 0.54 | 0.58 | 0.81 | 0.90 | 1.00 | 1.13 | 1.32 | 1.69 | 1.89 | 1.89 | |
| Pre-tax income | 0.30 | 0.33 | 0.39 | 0.43 | 0.44 | 0.44 | 0.42 | 0.52 | 0.52 | 0.73 | 0.88 | 0.96 | 1.10 | 1.26 | 1.68 | 1.92 | 1.92 | |
| Income tax | 0.08 | 0.08 | 0.08 | 0.09 | 0.08 | 0.09 | 0.08 | 0.21 | 0.11 | 0.11 | 0.41 | 0.18 | 0.20 | 0.24 | 0.28 | 0.40 | 0.40 | |
| Net income | 0.23 | 0.25 | 0.31 | 0.35 | 0.35 | 0.35 | 0.34 | 0.32 | 0.40 | 0.62 | 0.47 | 0.78 | 0.90 | 1.02 | 1.40 | 1.52 | 1.52 | |
| Diluted EPS ($) | 1.44 | 1.71 | 2.10 | 2.39 | 2.47 | 2.49 | 2.40 | 2.19 | 2.80 | 4.27 | 3.24 | 5.30 | 6.09 | 6.92 | 9.51 | 10.43 | 10.43 | |
| Diluted shares (bn) | 0.157 | 0.149 | 0.146 | 0.144 | 0.143 | 0.142 | 0.142 | 0.144 | 0.144 | 0.146 | 0.146 | 0.147 | 0.147 | 0.148 | 0.147 | 0.146 | — |
USD billions · SEC XBRL
ResMed Inc. — questions
- What is ResMed Inc.'s revenue?
- $5.7B over the twelve months to 2026-06-30, up 9.9% year on year, from its 10-Q and 10-K filings.
- What is ResMed Inc.'s net income?
- $1.5B over the twelve months to 2026-06-30.
- What is ResMed Inc.'s free cash flow?
- $1.6B over the twelve months to 2026-06-30.
- What are ResMed Inc.'s diluted earnings per share?
- $10.43 over the twelve months to 2026-06-30.
Every figure on this page comes from ResMed Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.